Loading…
The placement includes $150 million of committed capital.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced a structured private placement to raise up to $250 million, with $150 million already committed. The funds are intended to support the development of Seralutinib through potential FDA approval.
The total private placement amount is $250 million, with $150 million already secured in committed capital.
Gossamer Bio, Inc. has a free float of 128,763,768 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.